Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET
Company Participants
Caitlin Lowie - Vice President of Corporate Communications & Investor Relations
Mike Raab - President & Chief Executive Officer
Susan Rodriguez - Chief Commercial Officer
Justin Renz - Chief Financial Officer & Chief Operations Officer
Conference Call Participants
Louise Chen - Cantor
Yigal Nochomovitz - Citi Research
Joseph Thome - TD Cowen
Matt Kaplan - Ladenburg Thalmann
Operator
Good day and welcome to the Ardelyx Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
I would now like to turn the conference over to Caitlin Lowie vice President of Corporate Communications and Investor Relations at Ardelyx. Please go ahead.
Caitlin Lowie
Thank you. Good morning and welcome to our third quarter financial results call. During this call, we will refer to the press release issued earlier today which is available on the Investors section of the company's website at ardelyx.com.
During the call, we'll be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review the risk factors in our most recent quarterly report on Form 10-Q that was filed today and can be found on our website at ardelyx.com. Only elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our views change.
Our President and CEO, Mike Raab, will begin today's call with opening remarks and an overview of the company's progress during the third quarter of 2023. Next, Susan Rodriguez, Chief Commercial Officer, will provide an update on the performance of IBSRELA and the launch of XPHOZAH following its approval earlier this month. Justin Renz, Chief Financial and Operations Officer, will conclude today's prepared remarks with a review of the company's financial performance during the quarter ended September 30, 2023, before we open the call to questions.
With that, let me pass the call over to Mike.
Mike Raab
Good morning, everyone and thank you for joining us on the call. I'm very pleased to be here once again, just a short few weeks after we celebrated the approval of XPHOZAH. With this approval, we now have delivered on our mission to provide patients with medicines that matter for the second time. It is something I am immensely proud of.
Today, Susan, Justin and I will share details on the performance from the third quarter, as well as important updates from the first couple of weeks following -- in the fourth quarter following the announcement of XPHOZAH's approval.